Your eyes aren’t playing tricks on you. The price you’re paying for commonly purchased goods and services is rising.
In a growing economy, it’s perfectly normal for the price of goods and services to climb at a steady pace. But what we’ve witnessed recently is far from steady. In June, the Consumer Price Index for All Urban Consumers rose by 5.4% from the prior-year period. Minus energy and food, the Core Consumer Price Index jumped 4.5%.
Respectively, these are the highest year-over-year price increases since August 2008 and November 1991. In other words, the buying power of cash sitting on the sidelines is being eroded faster than it has been in over a decade.
However, the good news is that the stock market provides a solution. Buying value stocks would allow investors to take advantage of potential long-term share price appreciation, as well as collect a dividend payout, in many instances. After all, the vast majority of value stocks are profitable and have time-tested operating models.
The following four value stocks would be perfect to help investors trounce inflation.
Johnson & Johnson
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) has a lot going for it that would appeal to investors who want to outpace inflation. To begin with, J&J is one of only two publicly traded companies that holds a highly coveted AAA credit rating from Standard & Poor’s. That’s a higher credit than the U.S. government, and it implies that S&P has the utmost confidence in J&J’s ability to make good on its outstanding debts.
What really makes Johnson & Johnson tick is the company’s three operating segments, each of which is an important piece of the puzzle. For instance, its consumer healthcare products segment is slow-growing, but it has strong pricing power and generates predictable cash flow. There’s also the medical device division, which has grown slowly of late, but is perfectly set up to take advantage of an aging U.S. and global population.
Lastly, pharmaceuticals are responsible for the bulk of J&J’s margins and growth in the near term, although brand-name drugs have a finite period of sales exclusivity. These operating segments have worked together flawlessly to consistently push Johnson & Johnson’s adjusted operating earnings higher year after year.
We’re well past the point where J&J is going to floor Wall Street with its growth prospects. However, Johnson & Johnson has the potential to deliver high single-digit earnings growth and maintain its 59-year streak of base annual dividend increases, all while being valued at roughly 16 times Wall Street’s forward-year profit estimate. Its 2.4% yield and share price appreciation potential should be more than enough to put inflation in its place.
Philip Morris International
If you’re interested in a company where the dividend payout will do more of the heavy lifting, tobacco stock Philip Morris International (NYSE:PM) is a stock that can smoke inflation. Philip Morris ended this past week with a yield nearing 5%.
It’s no secret that a number of developed markets around the world are waging a war against tobacco and the negative effects associated with its use. Thankfully, Philip Morris’ geographic reach is a major advantage. With a presence in more than 180 countries worldwide, Philip Morris is able to offset volume weakness in markets where regulation is picking up with emerging markets where tobacco is still viewed as a luxury by a burgeoning middle class. Between its geographic diversity and the exceptionally strong pricing power associated with tobacco cigarettes, Philip Morris has had little issue growing its sales.
This is a company that’s looking to the future, as well. Sales of the IQOS heated tobacco system have soared, with heated tobacco unit shipment volume jumping 30% in the first half of 2021, compared to the previous year. Innovation on the smokeless tobacco front will further help Philip Morris offset any tobacco cigarette volume weakness it’s contending with in developed markets.
Tobacco isn’t the growth story it once was, but that hasn’t stopped Philip Morris from continuing to deliver for its shareholders.
Walgreens Boots Alliance
Johnson & Johnson isn’t the only value-focused healthcare stock that can help investors navigate their way through an environment of rapidly rising prices. Pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) and its market-topping 4.1% dividend yield can help investors crush inflation.
Walgreens is well into a multiyear turnaround plan that’s designed to improve its operating efficiency and jump-start its organic growth. By the end of fiscal 2022, the company anticipates having reduced its operating expenses by north of $2 billion.
Yet, in spite of these cost cuts, Walgreens has spent aggressively to digitize its systems and promote direct-to-consumer sales. Although online retail makes up only a small percentage of its total sales, it’s a segment that offers sustainable double-digit growth for the foreseeable future.
Arguably even more exciting for Walgreens is the partnership it announced with VillageMD in July 2020. This duo plans to open as many as 700 full-service clinics co-located in Walgreens’ stores in over 30 U.S. markets. Whereas most co-located clinics can only handle so much as a sniffle, this full-service partnership, complete with onsite physicians, could draw repeat patients, improve brand loyalty, and drive business to Walgreens’ higher-margin pharmacy segment.
At less than 10 times forward earnings, Walgreens is just what the doctor ordered for investors concerned about inflation.
Full story on Fool.com
Leave a Comment